



FOR IMMEDIATE RELEASE

Contact: Adam Rubenstein arubenstein@onbiovc.com (303) 902-4413	Web http://OnBioVC.com Twitter @OnBioVC Facebook http://facebook.com/OnBioVC LinkedIn http://linkedin.com/OnBioVC
--	---

OnBioVC RELEASES WHITE PAPER – A IS FOR INNOVATION AND ...

An Analysis of the 4Q11 Allocation of Bioscience Risk Capital

Boulder, CO (PR Web) March 14, 2012 – OnBioVC, the industry leader in organizing and reporting life science private venture financings, today announced the release of its latest white paper, “A is for Innovation And ... The 4Q11 Allocation of Early-Stage Risk Capital”. 2011 observed an increase in Series A financings relative to recent years (2008 to present). A dramatic acceleration of these early-stage financings occurred in the final quarter of the year, where of the 93 total first time institutional financings tracked, 40 announced closings transpired in 4Q11. The paper examines the 150% quarter-over-quarter growth (40, 4Q11 v. 16, 4Q10) in Series A financings and analyzes the types of companies who were recipients of this sharp increase in risk capital. OnBioVC findings indicate that the financing of early-stage ‘innovation’, defined as preclinical therapeutic products, is robust and on par relative to more mature therapeutic product candidates. Additionally, de-risked or those more clinically advanced therapeutic, device, diagnostic and health-IT products likewise increased their capture of Series A venture dollars.

“A heated debate is raging regarding who exactly were the recipients of the fourth quarter spike in venture dollars – many believe that innovation has recently suffered from a lack of funding while reconstituted products and late-stage assets have benefited from the lions share of risk capital,” said Adam Rubenstein, Managing Editor of OnBioVC. “We are pleased to present our 4Q11 Series A analysis detailing who are the companies that announced closing of their first institutional financing throughout the final twelve weeks of 2011 and details of their sector participation, product type, and development-stages.”

About OnBioVC

OnBioVC, an Indicium Data Company, the industry leader in organizing and reporting life science private venture financings, provides timely coverage and comprehensive analysis of global life science private and public capital investment, M&A and IPO activity. Quarterly published reports parse out transactional activity of private therapeutic, diagnostic, medical device, medical-IT and biofuel companies. The companion site, OnBioVC.com, provides deal data that is searchable by aggregate dollars raised via round, region, state, industry sector, indications and technologies as well as tagging the venture funds participating in individual financings. For more information please visit <http://OnBioVC.com>.

###